Apr 25 |
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
|
Apr 25 |
Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies
|
Apr 25 |
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
|
Apr 25 |
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
|
Apr 25 |
Regeneron expands in gene editing with Mammoth deal
|
Apr 24 |
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
|
Apr 24 |
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
|
Apr 22 |
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
|
Apr 22 |
Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
|
Apr 19 |
Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
|